Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
144000000
yenWording
Definitive
How definitive the wording is.Agreements reached under this partnership
4593HEALIOS K.K.
Alliance partner株式会社JENECELL
About the partner
Business DescriptionDevelops innovative products using advanced technologies across a range of fields, including pharmaceuticals, medical devices and cosmetics, based on stem cells. In particular, through its premium cosmetics business based on stem cell culture supernatant fluid, the company is advancing the development of high-performance skincare products.
LocationSeoul, South Korea
Impact on Business Performance
This revenue will be recognized in the fourth quarter of the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Name of alliance partner | 株式会社JENECELL |
| Alliance partner's business activities | Develops innovative products using advanced technologies across a range of fields, including pharmaceuticals, medical devices and cosmetics, based on stem cells. In particular, through its premium cosmetics business based on stem cell culture supernatant fluid, the company is advancing the development of high-performance skincare products. |
| Alliance partner's location | Seoul, South Korea |
| Impact on Business Performance | This revenue will be recognized in the fourth quarter of the fiscal year ending December 2026. |
Items this document does not state (19)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeType of allianceDetails of the allianceNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This represents the first commercial shipment in the product line based on cell culture supernatant and a concrete step toward securing revenue opportunities following the regenerative medicine pipeline.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.